KRAS and neoplasm: Among the clinical factors including: tumor size, age, gender, stage, histology, smoking history, receipt of adjuvant chemotherapy, DFS, OS, disease relapse, development of metastasis, development of brain metastasis, and survival status; only age was significantly different between cases with a K-ras mutation and those that were pan-wildtype (p = 0.048)(Table S1).